» Articles » PMID: 19224838

Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States from 1975 to 2005

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2009 Feb 20
PMID 19224838
Citations 758
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts.

Methods: Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted incidence and cause-specific survival rates from 1992 to 2005 were examined in the SEER 13 registries by race/ethnicity, stage, and treatment. United States liver cancer mortality rates were also examined.

Results: Age-adjusted HCC incidence rates tripled between 1975 and 2005. Incidence rates increased in each 10-year birth cohort from 1900 through the 1950s. Asians/Pacific Islanders had higher incidence and mortality rates than other racial/ethnic groups, but experienced a significant decrease in mortality rates over time. From 2000 to 2005, marked increases in incidence rates occurred among Hispanic, black, and white middle-aged men. Between 1992 and 2004, 2- to 4-year HCC survival rates doubled, as more patients were diagnosed with localized and regional HCC and prognosis improved, particularly for patients with reported treatment. Recent 1-year survival rates remained, however, less than 50%.

Conclusion: HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. Screening of at-risk groups and treatment of localized-stage tumors may contribute to increasing HCC survival rates in the United States. More progress is needed.

Citing Articles

The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics.

Lin H, Jeon A, Chen K, Lee C, Wu L, Chong S Br J Cancer. 2025; .

PMID: 40057667 DOI: 10.1038/s41416-025-02969-8.


Application of Indirect ELISA and PCR Techniques for Detecting of Hepatocellular Carcinoma using Des-gamma Carboxyprothrombin, Alpha-fetoprotein, and Thioredoxin Biomarkers.

Huy D, Khai N, Thinh T, Linh B, Minh N, Thuy V Mol Biotechnol. 2025; .

PMID: 39998774 DOI: 10.1007/s12033-025-01401-z.


Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases.

Chang B, Tian H, Huang A, Zhai X, Wang Q, Han L eGastroenterology. 2025; 2(1):e100036.

PMID: 39944749 PMC: 11731072. DOI: 10.1136/egastro-2023-100036.


Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma.

Guarneri V, Loggi E, Ramacieri G, Serra C, Vukotic R, Vitale G Cancers (Basel). 2025; 17(2).

PMID: 39857948 PMC: 11763969. DOI: 10.3390/cancers17020167.


Transcriptomic landscape of Hras12V oncogene-induced hepatocarcinogenesis with gender disparity.

Di H, Rong Z, Mao N, Li H, Chen J, Liu R BMC Cancer. 2025; 25(1):94.

PMID: 39819515 PMC: 11737189. DOI: 10.1186/s12885-025-13476-7.


References
1.
Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling R . Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int. 2007; 27(10):1394-401. DOI: 10.1111/j.1478-3231.2007.01596.x. View

2.
El-Serag H, Hampel H, Javadi F . The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4(3):369-80. DOI: 10.1016/j.cgh.2005.12.007. View

3.
Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A . Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004; 127(5 Suppl 1):S17-26. DOI: 10.1053/j.gastro.2004.09.012. View

4.
Yu L, Sloane D, Guo C, Howell C . Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol. 2006; 4(3):355-60. DOI: 10.1016/j.cgh.2005.12.022. View

5.
Kim H, Fay M, Feuer E, Midthune D . Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3):335-51. DOI: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. View